Sensei Biotherapeutics, Inc. announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo (cemiplimab). The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo® in a Phase 1/2 trial in solid tumors. Sensei is on track to submit an Investigational New Drug application for SNS-101 in or before April 2023 and the trial is expected to commence in 2023 pending regulatory clearance.

Under the terms of the agreement, Sensei will sponsor and fund the planned clinical trial and Regeneron will provide Libtayo. Sensei will maintain global development and commercial rights to SNS-101. Regeneron develops and commercializes Libtayo globally.

SNS-101 is currently under preclinical development, and the safety and efficacy of SNS-101 or its administration with Libtayo have not been reviewed by any regulatory authorities.